PMID- 37752767
OWN - NLM
STAT- MEDLINE
DCOM- 20240131
LR  - 20240206
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 42
IP  - 1
DP  - 2024 Jan
TI  - Comparison of autologous, matched sibling, and alternative donor stem cell 
      transplant outcomes for acute myeloid leukemia patients in first remission: A 
      propensity score matching study.
PG  - e3230
LID - 10.1002/hon.3230 [doi]
AB  - Autologous hematopoietic stem cell transplantation (auto-HSCT), matched sibling 
      donor HSCT (MSD-HSCT), and alternative donor HSCT (AD-HSCT) are viable 
      post-remission treatment options for acute myeloid leukemia (AML). A total of 283 
      de novo favorable- and intermediate-risk AML patients, based on the ELN 2022 
      criteria, in first complete remission were initially included for propensity 
      score matching. Following the matching process, 126 patients were selected for 
      further analysis, with 42 patients in each of the auto-HSCT, MSD-HSCT, and 
      AD-HSCT groups. Among the AD-HSCT group, 38 of 42 (90.5%) patients received 
      haploidentical HSCT. In patients with persistent undetectable measurable residual 
      disease (uMRD) before transplant (n = 83), overall survival (OS) was similar 
      across the groups. However, auto-HSCT showed a trend of increased disease-free 
      survival (DFS) compared to AD-HSCT (HR 2.85, P = 0.09), resulting in a 3-year DFS 
      and OS of 79.1% and 82.8%, respectively. In the non-persistent uMRD group 
      (n = 38), auto-HSCT exhibited a tendency to increase the risk of relapse, 
      particularly when compared to AD-HSCT (HR 0.24, P = 0.07), but this did not 
      result in inferior OS. The monthly direct medical cost per patient within the 
      first 2 years after HSCT was significantly lower in auto-HSCT compared to 
      MSD-HSCT (P = 0.015) and AD-HSCT (P < 0.001). Our results provide evidence for 
      the use of auto-HSCT as a viable therapeutic option for favorable- and 
      intermediate-risk de novo AML patients in first complete remission with 
      persistent uMRD. Additionally, our findings demonstrated a notable cost advantage 
      associated with auto-HSCT compared to MSD-HSCT and AD-HSCT.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Wang, Mingyang
AU  - Wang M
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Zhang, Haixiao
AU  - Zhang H
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Zheng, Xinhui
AU  - Zheng X
AUID- ORCID: 0000-0002-2082-7908
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Liu, Jia
AU  - Liu J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Wang, Jiali
AU  - Wang J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Cao, Yigeng
AU  - Cao Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Zhang, Xiaoyu
AU  - Zhang X
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Zhang, Rongli
AU  - Zhang R
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Chen, Xin
AU  - Chen X
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Zhai, Weihua
AU  - Zhai W
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Ma, Qiaoling
AU  - Ma Q
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Wei, Jialin
AU  - Wei J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Huang, Yong
AU  - Huang Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Yang, Donglin
AU  - Yang D
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - He, Yi
AU  - He Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Pang, Aiming
AU  - Pang A
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Feng, Sizhou
AU  - Feng S
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Han, Mingzhe
AU  - Han M
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
FAU - Jiang, Erlie
AU  - Jiang E
AUID- ORCID: 0000-0003-0237-6063
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
AD  - Tianjin Institutes of Health Science, Tianjin, China.
LA  - eng
GR  - CAMS Innovation Fund for Medical Sciences/
GR  - Haihe Laboratory of Cell Ecosystem Innovation Fund/
GR  - Key Project of Tianjin Natural Science Foundation/
GR  - Tianjin Health Science and Technology Project/
GR  - National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230926
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
SB  - IM
MH  - Humans
MH  - Siblings
MH  - Propensity Score
MH  - Tissue Donors
MH  - Stem Cell Transplantation
MH  - *Leukemia, Myeloid, Acute/therapy
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Retrospective Studies
OTO - NOTNLM
OT  - 2022 ELN
OT  - acute myeloid leukemia
OT  - allogeneic hematopoietic stem cell transplantation
OT  - autologous hematopoietic stem cell
EDAT- 2023/09/27 06:43
MHDA- 2024/01/31 06:42
CRDT- 2023/09/27 02:13
PHST- 2023/09/13 00:00 [revised]
PHST- 2023/03/22 00:00 [received]
PHST- 2023/09/14 00:00 [accepted]
PHST- 2024/01/31 06:42 [medline]
PHST- 2023/09/27 06:43 [pubmed]
PHST- 2023/09/27 02:13 [entrez]
AID - 10.1002/hon.3230 [doi]
PST - ppublish
SO  - Hematol Oncol. 2024 Jan;42(1):e3230. doi: 10.1002/hon.3230. Epub 2023 Sep 26.